Ublituximab for adults with Down syndrome regression disorder
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study tests a drug called ublituximab, given as an IV infusion, for adults with Down syndrome who have developed regression disorder and haven't fully improved with standard treatments. The goal is to see if this treatment can help improve daily functioning and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your loved one must be between 18 and 40 years old.
- Must have a diagnosis of Down syndrome (full or translocation type, not mosaic).
- Must have Down Syndrome Regression Disorder (DSRD) that is possible or probable, based on 2022 criteria.
- Must have tried at least one first-line treatment (like lorazepam, antidepressants, steroids, or IVIg) and it didn't fully help.
- Must be able to come to all study visits with a study partner or legal representative.
- Must not smoke tobacco (current or past).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if an investigational drug called AEF0217 can help improve thinking and daily living skills in people with Down syndrome. It's for ages 16-32 who have a caregiver to support them throughout the trial.
This study tests whether a drug called donanemab can lower amyloid plaques in the brains of adults with Down syndrome who are at risk for Alzheimer's disease. The goal is to see if it can slow or prevent memory and thinking problems.
This research study aims to better understand Down syndrome by collecting health information, family history, and sometimes brain imaging or sleep data from children and adults with Down syndrome and their families. The goal is to advance knowledge that could improve health and development for people with Down syndrome.
This study is testing how safe and effective the medication ublituximab is for older adults (ages 55–80) with relapsing multiple sclerosis. It aims to see if this treatment works well for this age group.
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
This study tests if an oral medication called tofacitinib can help the immune system work better in children and young adults with Down syndrome, which may improve learning and development. The study will follow participants for 6 months.
Hear when a new Down Syndrome (Trisomy 21) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.